- Antibiotics
- Anti-Diarrheal
- Immune System Suppressants
- Analgesics
- Anti-Inflammatory Drugs
- Monoclonal Antibodies
Crohn's Disease Treatment Market size valued at USD 800 million in 2022 and expected to reach USD 1088.7 million by 2028, at a significant CAGR of 4.5% from 2023-2029. A Crohns disease belongs to a condition called inflammatory bowel disease (IBD) that causes inflammation and damage to the digestive tract. Crohns disease usually affects at the end of small intestine and beginning of colon, but inflammation may occur anywhere along the digestive tract. crohns disease may be hereditary or develop due to the malfunctioning of the immune system. Currently there is no cure for crohn's disease. However, there are many treatments to manage disease symptoms. Inflammation, ulcers, bowel obstruction, malnutrition, colon cancer, and anal fissures are some of the complications associated with the disease. Surgery and drug therapy are some of the treatment options available to treat crohns disease. Some of the anti-inflammatory drugs used to treat crohns disease include, corticosteroids and oral 5-aminosalicylates. Global crohns disease treatment market is expected to grow at a significant rate during the forecast period.
Growth in biologics development unfolded the opportunities for the new market players as they are most commonly used in crohns disease treatment. Market players are focusing on to develop new products that can treat crohns disease. For instance, mongersen, is investigational therapy for the treatment of crohns disease, is being developed by Celgene Corporation in phase 3 clinical trials. Considering the foreseen factors crohns disease treatment market is projected to have a lucrative opportunity for market players. Manufacturers of Crohn's disease medications are concentrating on commercial distribution through retail pharmacies and online portals. Anti-inflammatory medications and corticosteroids are routinely distributed through these channels, both with and without a prescription. Consumers might also get savings when buying drugs in bulk through online platforms. The substantial rise of the anti-inflammatory medications segment of the global Crohn's disease market is mostly due to easy product availability and price cuts.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
The prime driver for global crohns disease treatment market is increase in number of people being infected by the disease. In addition, increase in demand for biologics and high unmet needs within the anti-TNF refractory patient group that presents untapped market opportunities. Strong pipeline and novel mechanisms to treat crohns disease are fueling the growth of global crohns disease treatment market . However, patent expiry of the key drugs and high cost of treatment is expected to hamper the crohns disease treatment market globally. High R&D investment for development of biological drugs and unknown etiology of the crohns disease further hindering the market growth.
The Crohn’s disease treatment market size was valued at USD 800 million in 2022.
The Crohn’s disease treatment market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
The Crohn’s disease treatment market key players Allergan, Inc. (U.S.), AbbVie Inc., (U.S.), Takeda Pharmaceutical Company Limited (Japan), Bayer AG (Switzerland), UCB S.A. (Belgium), Perrigo Company plc (Ireland), Pfizer Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S), Ferring B.V. (Switzerland)
1.Executive Summary |
2.Global Crohns Disease Treatment Market Introduction |
2.1.Global Crohns Disease Treatment Market - Taxonomy |
2.2.Global Crohns Disease Treatment Market - Definitions |
2.2.1.Drug Class |
2.2.2.Distribution Channel |
2.2.3.Region |
3.Global Crohns Disease Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Crohns Disease Treatment Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Crohns Disease Treatment Market By Drug Class, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
5.1. Antibiotics |
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Anti-Diarrheal |
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Immune System Suppressants |
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Analgesics |
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Anti-Inflammatory Drugs |
5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. Monoclonal Antibodies |
5.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
6.Global Crohns Disease Treatment Market By Distribution Channel, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
6.1. Hospital Pharmacy |
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Retail Pharmacy |
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Others |
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
7.Global Crohns Disease Treatment Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
7.1. North America |
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Europe |
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Asia Pacific (APAC) |
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Middle East and Africa (MEA) |
7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. Latin America |
7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
8.North America Crohns Disease Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
8.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.1.1.Antibiotics |
8.1.2.Anti-Diarrheal |
8.1.3.Immune System Suppressants |
8.1.4.Analgesics |
8.1.5.Anti-Inflammatory Drugs |
8.1.6.Monoclonal Antibodies |
8.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.2.1.Hospital Pharmacy |
8.2.2.Retail Pharmacy |
8.2.3.Others |
8.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.3.1.United States of America (USA) |
8.3.2.Canada |
9.Europe Crohns Disease Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
9.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Antibiotics |
9.1.2.Anti-Diarrheal |
9.1.3.Immune System Suppressants |
9.1.4.Analgesics |
9.1.5.Anti-Inflammatory Drugs |
9.1.6.Monoclonal Antibodies |
9.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Hospital Pharmacy |
9.2.2.Retail Pharmacy |
9.2.3.Others |
9.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Germany |
9.3.2.France |
9.3.3.Italy |
9.3.4.United Kingdom (UK) |
9.3.5.Spain |
9.3.6.Rest of EU |
10.Asia Pacific (APAC) Crohns Disease Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
10.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Antibiotics |
10.1.2.Anti-Diarrheal |
10.1.3.Immune System Suppressants |
10.1.4.Analgesics |
10.1.5.Anti-Inflammatory Drugs |
10.1.6.Monoclonal Antibodies |
10.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Hospital Pharmacy |
10.2.2.Retail Pharmacy |
10.2.3.Others |
10.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.China |
10.3.2.India |
10.3.3.Australia and New Zealand (ANZ) |
10.3.4.Japan |
10.3.5.Rest of APAC |
11.Middle East and Africa (MEA) Crohns Disease Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
11.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Antibiotics |
11.1.2.Anti-Diarrheal |
11.1.3.Immune System Suppressants |
11.1.4.Analgesics |
11.1.5.Anti-Inflammatory Drugs |
11.1.6.Monoclonal Antibodies |
11.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Hospital Pharmacy |
11.2.2.Retail Pharmacy |
11.2.3.Others |
11.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.GCC Countries |
11.3.2.South Africa |
11.3.3.Rest of MEA |
12.Latin America Crohns Disease Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
12.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Antibiotics |
12.1.2.Anti-Diarrheal |
12.1.3.Immune System Suppressants |
12.1.4.Analgesics |
12.1.5.Anti-Inflammatory Drugs |
12.1.6.Monoclonal Antibodies |
12.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Hospital Pharmacy |
12.2.2.Retail Pharmacy |
12.2.3.Others |
12.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Brazil |
12.3.2.Mexico |
12.3.3.Rest of LA |
13. Competition Landscape |
13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
13.2.1.Allergan, Inc. (U.S.) |
13.2.2.AbbVie Inc., (U.S.) |
13.2.3.Takeda Pharmaceutical Company Limited (Japan) |
13.2.4.Bayer AG (Switzerland) |
13.2.5.UCB S.A. (Belgium) |
13.2.6.Perrigo Company plc (Ireland) |
13.2.7.Pfizer Inc. (U.S.) |
13.2.8.Johnson & Johnson Services, Inc. (U.S) |
13.2.9.Ferring B.V. (Switzerland) |
14. Research Methodology |
15. Appendix and Abbreviations |